[go: up one dir, main page]

DE4343034C1 - Verwendung von Pentoxifyllin zur Behandlung von Multipler Sklerose - Google Patents

Verwendung von Pentoxifyllin zur Behandlung von Multipler Sklerose

Info

Publication number
DE4343034C1
DE4343034C1 DE4343034A DE4343034A DE4343034C1 DE 4343034 C1 DE4343034 C1 DE 4343034C1 DE 4343034 A DE4343034 A DE 4343034A DE 4343034 A DE4343034 A DE 4343034A DE 4343034 C1 DE4343034 C1 DE 4343034C1
Authority
DE
Germany
Prior art keywords
day
treatment
pentoxifylline
patient
ptx
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE4343034A
Other languages
German (de)
English (en)
Inventor
Peter Dr Med Rieckmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dr Rentschler & Co Medizin Kg 88471 Lauphe GmbH
Original Assignee
Dr Rentschler Arzneimittel GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DE4343034A priority Critical patent/DE4343034C1/de
Application filed by Dr Rentschler Arzneimittel GmbH and Co KG filed Critical Dr Rentschler Arzneimittel GmbH and Co KG
Priority to PL94314588A priority patent/PL314588A1/xx
Priority to PCT/EP1994/004188 priority patent/WO1995016450A1/fr
Priority to CA002176848A priority patent/CA2176848A1/fr
Priority to EP95904491A priority patent/EP0734262A1/fr
Priority to SK766-96A priority patent/SK76696A3/sk
Priority to JP7516543A priority patent/JPH09506603A/ja
Priority to FI962473A priority patent/FI962473L/fi
Priority to CZ961708A priority patent/CZ170896A3/cs
Application granted granted Critical
Publication of DE4343034C1 publication Critical patent/DE4343034C1/de
Priority to NO962503A priority patent/NO962503D0/no
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE4343034A 1993-12-16 1993-12-16 Verwendung von Pentoxifyllin zur Behandlung von Multipler Sklerose Expired - Fee Related DE4343034C1 (de)

Priority Applications (10)

Application Number Priority Date Filing Date Title
DE4343034A DE4343034C1 (de) 1993-12-16 1993-12-16 Verwendung von Pentoxifyllin zur Behandlung von Multipler Sklerose
PCT/EP1994/004188 WO1995016450A1 (fr) 1993-12-16 1994-12-16 Utilisation de la pentoxyfylline dans le traitement de la sclerose en plaques
CA002176848A CA2176848A1 (fr) 1993-12-16 1994-12-16 Utilisation de la pentoxyfylline dans le traitement de la sclerose en plaques
EP95904491A EP0734262A1 (fr) 1993-12-16 1994-12-16 Utilisation de la pentoxyfylline dans le traitement de la sclerose en plaques
PL94314588A PL314588A1 (en) 1993-12-16 1994-12-16 Application of pentoxyphyline in treatment of sclerosis multiplex
SK766-96A SK76696A3 (en) 1993-12-16 1994-12-16 Pentoxifyllin allone or in combination with corticosteroid
JP7516543A JPH09506603A (ja) 1993-12-16 1994-12-16 多発性硬化症治療でのペントキシフィリンの使用
FI962473A FI962473L (fi) 1993-12-16 1994-12-16 Pentoksifylliinin käyttö pesäkovettumataudin käsittelemiseksi
CZ961708A CZ170896A3 (en) 1993-12-16 1994-12-16 The use of pentoxyphylline for preparing a medicament for treating sclerosis multiplex disease and pharmaceutical composition containing thereof
NO962503A NO962503D0 (no) 1993-12-16 1996-06-13 Anvendelse av penoksyfyllin ved behandling av multippel sklerose

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4343034A DE4343034C1 (de) 1993-12-16 1993-12-16 Verwendung von Pentoxifyllin zur Behandlung von Multipler Sklerose

Publications (1)

Publication Number Publication Date
DE4343034C1 true DE4343034C1 (de) 1995-06-08

Family

ID=6505251

Family Applications (1)

Application Number Title Priority Date Filing Date
DE4343034A Expired - Fee Related DE4343034C1 (de) 1993-12-16 1993-12-16 Verwendung von Pentoxifyllin zur Behandlung von Multipler Sklerose

Country Status (10)

Country Link
EP (1) EP0734262A1 (fr)
JP (1) JPH09506603A (fr)
CA (1) CA2176848A1 (fr)
CZ (1) CZ170896A3 (fr)
DE (1) DE4343034C1 (fr)
FI (1) FI962473L (fr)
NO (1) NO962503D0 (fr)
PL (1) PL314588A1 (fr)
SK (1) SK76696A3 (fr)
WO (1) WO1995016450A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19544768C1 (de) * 1995-11-30 1997-07-10 Rentschler Arzneimittel Verwendung einer Kombination aus Pentoxifyllin mit Typ-I-Interferonen zur Behandlung der Multiplen Sklerose
WO2001032156A3 (fr) * 1999-11-02 2002-09-26 Univ Dalhousie Traitements de maladies fibroproliferantes
WO2007041506A1 (fr) * 2005-10-03 2007-04-12 Melior Discovery, Inc. Formules de purines et méthodes pour prendre en charge des troubles

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001087280A2 (fr) * 2000-05-15 2001-11-22 Bayer Aktiengesellschaft Moyen permettant de traiter les poussees de maladies auto-immunes
EP3750560A3 (fr) * 2012-10-09 2021-03-24 Biogen MA Inc. Polythérapies et utilisations pour le traitement de troubles de démyélinisation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4307883A1 (en) * 1992-03-12 1993-09-23 Westarp Martin Egon Dr Med Use of anti-retroviral substances - to treat motor-neuronal diseases
US5763446A (en) * 1992-03-26 1998-06-09 University Of Southern California Use of pentoxifylline and other tumor necrosis factor blockers for the treatment of aids-associated optic neuropathy and other central nervous system diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NICHTS ERMITTELT *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19544768C1 (de) * 1995-11-30 1997-07-10 Rentschler Arzneimittel Verwendung einer Kombination aus Pentoxifyllin mit Typ-I-Interferonen zur Behandlung der Multiplen Sklerose
WO2001032156A3 (fr) * 1999-11-02 2002-09-26 Univ Dalhousie Traitements de maladies fibroproliferantes
WO2007041506A1 (fr) * 2005-10-03 2007-04-12 Melior Discovery, Inc. Formules de purines et méthodes pour prendre en charge des troubles

Also Published As

Publication number Publication date
CZ170896A3 (en) 1997-01-15
FI962473A7 (fi) 1996-07-16
EP0734262A1 (fr) 1996-10-02
NO962503L (no) 1996-06-13
SK76696A3 (en) 1997-04-09
PL314588A1 (en) 1996-09-16
NO962503D0 (no) 1996-06-13
JPH09506603A (ja) 1997-06-30
WO1995016450A1 (fr) 1995-06-22
FI962473L (fi) 1996-07-16
CA2176848A1 (fr) 1995-06-22
FI962473A0 (fi) 1996-06-14

Similar Documents

Publication Publication Date Title
DE2856393C2 (de) Arzneimittel zur Behandlung von Morbus Parkinson
DE69230046T2 (de) 2-Bromomelatonin zur Behandlung von Schlafstörungen
DE69827853T2 (de) Verwendung von Ibudilast zur Herstellung eines Arzneimittels zur Behandlung von multipler Sklerose
DE69232016T2 (de) Pharmazeutische zusammensetzung, die gamma-hydroxybuttersäure oder das entsprechende lakton enthält, zur behandlung von drogenabhängigkeit und ernährungsstörungen
DE19521684C2 (de) Pharmazeutische Zusammensetzung zur ophthalmologischen Anwendung
EP0188810A2 (fr) Utilisation de dérivés dipeptidiques pour la prévention ou le traitement de dommages post-traumatiques des nerfs crâniers et/ou cérébrospinaux
EP0185210B1 (fr) Utilisation de dérivés dipeptidiques pour la préparation de médicaments pour le traitement des malades atteints de sclérose latérale amyotrophique
DE60214527T2 (de) Verwendung von flumazenil bei der entwicklung eines arzneimittels zur behandlung von alkoholabhängigkeit
DE3530767C2 (fr)
DE3116860C2 (fr)
DE4343034C1 (de) Verwendung von Pentoxifyllin zur Behandlung von Multipler Sklerose
DE60015098T2 (de) 3-cyclopropylmethoxy-4-difluormethoxy-n-(3,5-dichlor-pyrid-4-yl)-benzamid zur behandlung von multipler sklerose
DE19544768C1 (de) Verwendung einer Kombination aus Pentoxifyllin mit Typ-I-Interferonen zur Behandlung der Multiplen Sklerose
DE69131553T2 (de) Arzneimittel enthaltend Mischungen von höheren primären aliphatischen Alkoholen zur Behandlung von Hypercholesterolämie und Hyperlipoproteinämie Typ II und zur Stimulation des sexuellen Verhaltens bei Tieren und Menschen
EP0345247A2 (fr) Utilisation de derivés organiques monosubstitués du selenium pour la préparation d'un médicament, le médicament et sa préparation
DE2206570B2 (de) Verwendung von ( + ) - Catechin
EP1001756B1 (fr) Compositions a effet synergique pour lutter selectivement contre les tissus tumoraux
DE69821970T2 (de) Verwendung von CITICOLINE ZUR BEHANDLUNG VON MULTIPLER SKLEROSE
DE3875065T2 (de) Verwendung von nalmefen zur herstellung eines arzneimittels zur behandlung der schaedigung des zentralnervensystems.
DE2145357C2 (de) Arzneimittelzubereitung, enthaltend Natrium-Dantrolen
EP0604830B1 (fr) Utilisation d'au moins un antagoniste du PAF dans la fabrication d'un médicament pour le traitement ou la prévention de l'hyperinsulinisme
Kuhn et al. Pharmacology and hypnogenic properties of brotizolam in animals.
DE3136455C2 (de) Verwendung von Caerulein oder dessen pharmazeutisch verträglichen Salzen bei der Bekämpfung von psychotischen Krankheitszuständen
DE69109933T2 (de) Verwendung von Mizoribin zur Behandlung oder Vorbeugung der Multiplen Sklerose.
DE2345377A1 (de) Pharmazeutische zubereitung i

Legal Events

Date Code Title Description
8100 Publication of patent without earlier publication of application
D1 Grant (no unexamined application published) patent law 81
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: DR. RENTSCHLER GMBH & CO. MEDIZIN KG, 88471 LAUPHE

8339 Ceased/non-payment of the annual fee